JP2018511303A - 抗サルモネラ抗体及びその使用 - Google Patents

抗サルモネラ抗体及びその使用 Download PDF

Info

Publication number
JP2018511303A
JP2018511303A JP2017541701A JP2017541701A JP2018511303A JP 2018511303 A JP2018511303 A JP 2018511303A JP 2017541701 A JP2017541701 A JP 2017541701A JP 2017541701 A JP2017541701 A JP 2017541701A JP 2018511303 A JP2018511303 A JP 2018511303A
Authority
JP
Japan
Prior art keywords
antibody
salmonella
antibody fragment
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017541701A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511303A5 (enExample
Inventor
アリ リアジー
アリ リアジー
ラシダ ウィリアムズ
ラシダ ウィリアムズ
ディア シャヒナス
ディア シャヒナス
サイード バベイ
サイード バベイ
ヂュン ヤン
ヂュン ヤン
Original Assignee
アブセレックス テクノロジーズ インコーポレイテッド
アブセレックス テクノロジーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アブセレックス テクノロジーズ インコーポレイテッド, アブセレックス テクノロジーズ インコーポレイテッド filed Critical アブセレックス テクノロジーズ インコーポレイテッド
Publication of JP2018511303A publication Critical patent/JP2018511303A/ja
Publication of JP2018511303A5 publication Critical patent/JP2018511303A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1235—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Salmonella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
JP2017541701A 2015-02-04 2016-02-03 抗サルモネラ抗体及びその使用 Pending JP2018511303A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562112035P 2015-02-04 2015-02-04
US62/112,035 2015-02-04
PCT/IB2016/050546 WO2016125089A1 (en) 2015-02-04 2016-02-03 Anti-salmonella antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020068020A Division JP2020120667A (ja) 2015-02-04 2020-04-06 抗サルモネラ抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2018511303A true JP2018511303A (ja) 2018-04-26
JP2018511303A5 JP2018511303A5 (enExample) 2019-03-07

Family

ID=56563529

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017541701A Pending JP2018511303A (ja) 2015-02-04 2016-02-03 抗サルモネラ抗体及びその使用
JP2020068020A Pending JP2020120667A (ja) 2015-02-04 2020-04-06 抗サルモネラ抗体及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020068020A Pending JP2020120667A (ja) 2015-02-04 2020-04-06 抗サルモネラ抗体及びその使用

Country Status (6)

Country Link
US (2) US10421806B2 (enExample)
EP (1) EP3253789A4 (enExample)
JP (2) JP2018511303A (enExample)
AU (1) AU2016214059B2 (enExample)
CA (1) CA2972568A1 (enExample)
WO (1) WO2016125089A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102165777B1 (ko) * 2016-04-06 2020-10-14 주무토르 바이오로직스 인코포레이티드 단백질의 클로닝 및 발현을 위한 벡터, 그 방법 및 적용
MX2020008208A (es) * 2018-02-05 2020-11-09 Orionis Biosciences Inc Agentes de unión a fibroblastos y uso de estos.
WO2021197358A1 (zh) * 2020-03-31 2021-10-07 普米斯生物技术(珠海)有限公司 一种抗pd-l1和pd-l2抗体及其衍生物和用途
CN112707963A (zh) * 2021-01-26 2021-04-27 西北农林科技大学 广谱识别沙门氏菌的纳米抗体、重组载体、宿主细胞及其应用
WO2025111553A2 (en) * 2023-11-22 2025-05-30 The General Hospital Corporation Antibody-based human lamp-1 composition and its uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915158A2 (en) * 1997-11-04 1999-05-12 Unilever N.V. Improvements in or relating to detection of salmonella
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
JP2014506454A (ja) * 2011-01-28 2014-03-17 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
WO2015145250A2 (en) * 2014-03-27 2015-10-01 Ghosh Sambuddha Expression of a single chain antibody against salmonella in lactobacillus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0915158A2 (en) * 1997-11-04 1999-05-12 Unilever N.V. Improvements in or relating to detection of salmonella
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
JP2014506454A (ja) * 2011-01-28 2014-03-17 ナショナル リサーチ カウンシル オブ カナダ 免疫グロブリンドメインの工学的作製
WO2015145250A2 (en) * 2014-03-27 2015-10-01 Ghosh Sambuddha Expression of a single chain antibody against salmonella in lactobacillus

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOWACKA, A.: "Isolation of Salmonella Serovar-Specific Single Domain Antibodies", A THESIS PRESENTED TO THE UNIVERSITY OF GUELPH, JPN6019051378, 2014, pages 1 - 132, ISSN: 0004332693 *

Also Published As

Publication number Publication date
US20200040067A1 (en) 2020-02-06
US10421806B2 (en) 2019-09-24
EP3253789A1 (en) 2017-12-13
EP3253789A4 (en) 2018-11-14
WO2016125089A1 (en) 2016-08-11
AU2016214059A1 (en) 2017-07-20
JP2020120667A (ja) 2020-08-13
US20180030120A1 (en) 2018-02-01
CA2972568A1 (en) 2016-08-11
AU2016214059B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
Hu et al. Characteristics, pathogenic mechanism, zoonotic potential, drug resistance, and prevention of avian pathogenic Escherichia coli (APEC)
JP2020120667A (ja) 抗サルモネラ抗体及びその使用
Riazi et al. Pentavalent single-domain antibodies reduce Campylobacter jejuni motility and colonization in chickens
US20210269512A1 (en) Antibodies against disease causing agents of poultry and uses thereof
US10259864B2 (en) Anti-campylobacter jejuni antibodies and uses therefor
US11939371B2 (en) Antibodies against microorganisms and uses thereof
RU2445364C2 (ru) Рекомбинантные аттенуированные микроорганизмы clostridium и вакцина
JP2010013454A (ja) グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体
JP2018511303A5 (enExample)
US20040086513A1 (en) Antibodies for preventing and treating attaching and effacing escherichia coli (aeec) associated diseases
JP2004514423A (ja) トランスジェニックｘｅｎｏｍｏｕｓｅ（登録商標）から獲得されるｐｅｕｄｏｍｏｎａｓａｅｒｕｇｉｎｏｓａｌｐｓに対するヒト抗体
AU2020202611A1 (en) Binding moieties for biofilm remediation
Quintard et al. Efficacy of an oral live vaccine for veterinary use against pseudotuberculosis
Hunault Identification and evaluation of monoclonal antibodies against Surface-Layer Proteins of Clostridioides difficile
CN118510541A (zh) 多价抗弯曲杆菌抗体和疫苗
Almario Prevalence of Salmonella on laying hen farms and control of colonization in poultry through egg yolk antibodies
Cooper Necrotic enteritis in broiler chickens: studies in disease reproduction and pathogenesis
Ghunaim Campylobacter jejuni colonization of broiler chickens
Kotzé Incidence of Staphylococcus aureus in cows' milk following mucosal and parenteral administration of autogenous S. aureus vaccine during the dry period

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200901